ezetimibe has been researched along with cytellin in 36 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (cytellin) | Trials (cytellin) | Recent Studies (post-2010) (cytellin) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 2,801 | 207 | 890 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (41.67) | 29.6817 |
| 2010's | 20 (55.56) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Kane, J; Kwiterovich, P; Lütjohann, D; Musliner, T; Musser, B; Patel, SB; Salen, G; Stein, P; von Bergmann, K | 1 |
| Klett, EL; Patel, SB | 1 |
| Frölich, JC; Pham, VV | 1 |
| Cohen, JC; Hobbs, HH; Lütjohann, D; von Bergmann, K; Yu, L | 1 |
| Patel, SB; Salen, G; Sisk, CM; Starc, T | 1 |
| Giessmann, T; Luetjohann, D; Oswald, S; Rosskopf, D; Siegmund, W; Wegner, D; Weitschies, W | 1 |
| Suzuki, H; Takada, T; Yamanashi, Y | 1 |
| Conejo-Mir, JS; Fernandez-Freire, LR; Guirado, SS; Muñoz, MA; Ortíz, JV; Wite, JB | 1 |
| Márk, L; Paragh, G | 1 |
| Assmann, G; Gutkin, SW; Kannenberg, F; Musliner, TA; Ramey, DR; Veltri, EP | 1 |
| Beers, L; Bleasby, K; Braun, M; Garcia, ML; Hafey, M; Kaczorowski, GJ; Köhler, MG; Leone, J; Liu, J; McCann, ME; Nketiah, EO; Schmalhofer, W; Smith, L; Tang, YS; Thomas, A; Ujjainwalla, F; Weinglass, AB; Williams, B | 1 |
| Hazen, SL; Sehayek, E | 1 |
| Cselovszky, D; Lütjohann, D; McCrary Sisk, C; Musliner, T; Salen, G; Sapre, A; Sirah, W; von Bergmann, K | 1 |
| Johnson-Levonas, AO; Lin, J; Lütjohann, D; Macdonell, G; Musliner, T; Sapre, A; Shah, A; Sirah, W; von Bergmann, K | 1 |
| Constantinides, PP; Darlington, J; Gershkovich, P; Sivak, O; Wasan, KM | 1 |
| Groen, AK; Hutten, BA; Jakulj, L; Kastelein, JJ; Lutjohann, D; Veltri, EP; Vissers, MN | 1 |
| Chong, KW; Ho, LT; Hsu, JH; Huang, CH; Kratz, LE; Kwok, CF; Lo, MY; Niu, DM; Wu, TJ; Yu, HC | 1 |
| Masuda, D; Nakagawa-Toyama, Y; Nishida, M; Ohama, T; Tsubakio-Yamamoto, K; Yamashita, S | 1 |
| Ishibashi, S; Kotani, K; Miyamoto, M; Nagasaka, S; Okada, K; Osuga, J; Yagyu, H | 1 |
| Lee, T | 1 |
| Davidson, MH | 1 |
| Doggrell, SA | 1 |
| Borges, NC; Fonseca, FA; Helfenstein, T; Izar, MC; Kasmas, SH; Moreira, FT; Moreno, RA; Ramos, SC; Rezende, VM; Silva, FC | 1 |
| Blum, D; Chaput, E; Derks, M; Kallend, D; Niesor, EJ; Staempfli, A | 1 |
| Lin, J; Lowe, RS; Schaefer, EJ; Shah, AK; Tershakovec, AM; Thongtang, N; Tomassini, JE | 1 |
| Genser, B; März, W; Nestel, P; Silbernagel, G | 1 |
| Aguirre, AC; Amaral, JB; Barbosa, SP; Bianco, HT; Fonseca, FA; França, CN; Izar, MC; Lins, LC; Matos, LN; Santana, JM | 1 |
| Jones, PJ; Myrie, SB; Othman, RA | 1 |
| Ballantyne, CM; Cain, VA; Hoogeveen, RC; Karlson, BW; Palmer, MK; Raya, JL | 1 |
| DeBarber, AE; Jones, PJH; Mymin, D; Myrie, SB; Othman, RA; Roullet, JB; Steiner, RD | 1 |
| Bastida, JM; Benito, R; Díez-Campelo, M; Girós, M; González-Porras, JR; Hernández-Rivas, JM; Hernández-Sánchez, JM; Hortal, A; Janusz, K; Lozano, ML; Marcellini, S; Rivera, J | 1 |
| Dembinski, T; Hatch, GM; Mymin, D; Salen, G; Triggs-Raine, B; Waggoner, DJ | 1 |
| Arashi, H; Endo, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Sekiguchi, H; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Laufs, U; Lütjohann, D; Schulze, PC; Weingärtner, O | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Dateki, S; Ikeda, K; Kashimada, K; Komiya, C; Mishima, H; Nakano, Y; Ogawa, Y; Shiba, K; Shimizu, H; Tsujimoto, K; Yamada, T; Yoshiura, KI | 1 |
7 review(s) available for ezetimibe and cytellin
| Article | Year |
|---|---|
[Change in the cholesterol metabolism associated with the combined inhibition of synthesis and absorption].
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol, Dietary; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Phytosterols; Sitosterols | 2007 |
Current therapy for patients with sitosterolemia--effect of ezetimibe on plant sterol metabolism.
Topics: Adolescent; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP-Binding Cassette Transporters; Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ileum; Ion Exchange Resins; Lipid Metabolism, Inborn Errors; Lipoproteins; Male; Models, Biological; Mutation, Missense; Phytosterols; Sitosterols; Young Adult | 2010 |
Therapies targeting exogenous cholesterol uptake: new insights and controversies.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; ATP-Binding Cassette Transporters; Azetidines; Bile Acids and Salts; Biological Transport; Cholesterol; Cholesterol, HDL; Drug Discovery; Ezetimibe; Humans; Intestinal Absorption; Metabolic Diseases; Mice; Molecular Targeted Therapy; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2 | 2011 |
Lowering LDL cholesterol with margarine containing plant stanol/sterol esters: is it still relevant in 2011?
Topics: Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Ezetimibe; Fibric Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Margarine; Micronutrients; Niacin; Phytosterols; Sitosterols; Triglycerides | 2011 |
Plant sterols and atherosclerosis.
Topics: Alleles; Animals; Anticholesteremic Agents; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol, LDL; Ezetimibe; Genetic Loci; Humans; Lipoproteins; Phytosterols; Phytotherapy; Randomized Controlled Trials as Topic; Risk Factors; Sitosterols | 2013 |
Non-cholesterol sterols and cholesterol metabolism in sitosterolemia.
Topics: Absorption; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Disease Progression; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Kinetics; Lipid Metabolism, Inborn Errors; Membrane Proteins; Membrane Transport Proteins; Phytosterols; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterols; Xanthomatosis | 2013 |
Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia.
Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; DNA Mutational Analysis; Ezetimibe; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Middle Aged; Mutation; Phenotype; Phytosterols; Sitosterols; Spain; Thrombocytopenia; Xanthomatosis | 2017 |
13 trial(s) available for ezetimibe and cytellin
| Article | Year |
|---|---|
Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Arteriosclerosis; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Child; Cholesterol; Cholesterol, Dietary; Double-Blind Method; Ezetimibe; Female; Genes, Recessive; Humans; Intestinal Absorption; Lipid Metabolism, Inborn Errors; Lipoproteins; Male; Middle Aged; Phytosterols; Sitosterols; Treatment Outcome | 2004 |
Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Azetidines; Cholesterol; Chromatography, Gas; Chromatography, Liquid; Cross-Over Studies; Enzyme Inhibitors; Ezetimibe; Feces; Female; Genotype; Glucuronides; Humans; Intestinal Absorption; Intestinal Mucosa; Intestines; Liver-Specific Organic Anion Transporter 1; Male; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters; Phytosterols; Rifampin; Sitosterols; Time Factors | 2006 |
Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Azetidines; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Phytosterols; Placebos; Simvastatin; Sitosterols; Sterols | 2008 |
Efficacy and safety of ezetimibe 40 mg vs. ezetimibe 10 mg in the treatment of patients with homozygous sitosterolaemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Humans; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Sitosterols; Treatment Outcome; Young Adult | 2008 |
Long-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension study.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticholesteremic Agents; Azetidines; Child; Double-Blind Method; Ezetimibe; Female; Homozygote; Humans; Hypercholesterolemia; Male; Middle Aged; Sitosterols; Treatment Outcome; Young Adult | 2008 |
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial.
Topics: Adult; Aged; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Phytosterols; Simvastatin; Sitosterols; Statistics as Topic | 2010 |
Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus.
Topics: Aged; Azetidines; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Cholestanol; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Ezetimibe; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phytosterols; Sitosterols | 2010 |
The role of soluble fiber intake in patients under highly effective lipid-lowering therapy.
Topics: Azetidines; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Dietary Fiber; Ezetimibe; Female; Fluorobenzenes; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Pyrimidines; Rosuvastatin Calcium; Sitosterols; Sulfonamides; Triglycerides | 2011 |
Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Topics: Amides; Animals; Anticholesteremic Agents; Azetidines; Biomarkers; Cholestanol; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cricetinae; Cross-Over Studies; Desmosterol; Esters; Ezetimibe; Homeostasis; Humans; Intestinal Absorption; Lipid Metabolism; Male; Mesocricetus; Models, Animal; Phytosterols; Quinolines; Sitosterols; Sulfhydryl Compounds; Switzerland | 2011 |
Effects of ezetimibe added to statin therapy on markers of cholesterol absorption and synthesis and LDL-C lowering in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Male; Middle Aged; Multivariate Analysis; Sitosterols; Time Factors; Treatment Outcome; United States | 2012 |
Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; C-Reactive Protein; Cardiovascular Diseases; Cholesterol; Desmosterol; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Phytosterols; Prospective Studies; Pyrroles; Risk Factors; Sitosterols; Statistics, Nonparametric | 2013 |
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.
Topics: Absorption; Adult; Atherosclerosis; Azetidines; Biomarkers; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lipoproteins; Male; Pyrimidines; Risk; Rosuvastatin Calcium; Simvastatin; Sitosterols; Sulfonamides; Treatment Outcome | 2014 |
Thyroid Hormone Status in Sitosterolemia Is Modified by Ezetimibe.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholestanol; Cholestenones; Cholesterol; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Phytosterols; Sitosterols; Thyrotropin; Thyroxine; Triiodothyronine; Young Adult | 2017 |
16 other study(ies) available for ezetimibe and cytellin
| Article | Year |
|---|---|
Biomedicine. Will the real cholesterol transporter please stand up.
Topics: Animals; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol, Dietary; Enterocytes; Ezetimibe; Humans; Intestinal Absorption; Intestine, Small; Lipoproteins; Liver; Membrane Proteins; Membrane Transport Proteins; Mice; Models, Biological; Proteins; Sitosterols | 2004 |
[Can ezetimib also be used as a treatment for beta-sitosterol].
Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Humans; Sitosterols | 2004 |
Ezetimibe normalizes metabolic defects in mice lacking ABCG5 and ABCG8.
Topics: Absorption; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP Binding Cassette Transporter, Subfamily G, Member 8; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Ezetimibe; Lipoproteins; Liver; Mice; Mice, Knockout; Phytosterols; Sitosterols; Sterols | 2005 |
Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.
Topics: Anticholesteremic Agents; Azetidines; Child; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Risk Assessment; Severity of Illness Index; Sitosterols; Treatment Outcome; Xanthomatosis | 2006 |
Niemann-Pick C1-like 1 overexpression facilitates ezetimibe-sensitive cholesterol and beta-sitosterol uptake in CaCo-2 cells.
Topics: Anticholesteremic Agents; Azetidines; Caco-2 Cells; Cholesterol; Ezetimibe; Humans; Membrane Transport Proteins; Micelles; Phosphatidylcholines; Sitosterols; Taurocholic Acid | 2007 |
Sitosterol xanthomatosis.
Topics: Azetidines; Ezetimibe; Female; Humans; Hypolipidemic Agents; Middle Aged; Sitosterols; Xanthomatosis | 2007 |
Madin-Darby canine kidney II cells: a pharmacologically validated system for NPC1L1-mediated cholesterol uptake.
Topics: Animals; Azetidines; beta-Lactams; Caco-2 Cells; Cell Line; Cholesterol; Cloning, Molecular; Dogs; Ezetimibe; Humans; Membrane Proteins; Membrane Transport Proteins; Reproducibility of Results; Sitosterols; Sulfonamides; Transfection; Tritium | 2008 |
Cholesterol absorption from the intestine is a major determinant of reverse cholesterol transport from peripheral tissue macrophages.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cell Line; Cell Transplantation; Cholesterol, Dietary; Ezetimibe; Feces; Female; Intestinal Absorption; Intestines; Kinetics; Lipid Metabolism; Macrophages; Mice; Mice, Congenic; Mice, Inbred C57BL; Sitosterols | 2008 |
Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds.
Topics: Aluminum Silicates; Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Ezetimibe; Intestinal Absorption; Male; Nanostructures; Particle Size; Protons; Rats; Rats, Sprague-Dawley; Sitosterols; Surface Properties; Viscosity | 2009 |
Clinical observations, molecular genetic analysis, and treatment of sitosterolemia in infants and children.
Topics: Anticholesteremic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily G, Member 5; ATP-Binding Cassette Transporters; Azetidines; Child; DNA Mutational Analysis; Ezetimibe; Female; Genetic Testing; Humans; Infant; Lipoproteins; Metabolism, Inborn Errors; Point Mutation; Sitosterols | 2010 |
Ask the doctor. I have tried all of the statin drugs to lower my cholesterol, but each one has caused severe muscle pain. Are there any non-statin medications I could try using to lower my cholesterol?
Topics: Allylamine; Azetidines; Colesevelam Hydrochloride; Diet, Mediterranean; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Pain; Sitosterols | 2010 |
The natural history of phytosterolemia: Observations on its homeostasis.
Topics: Adolescent; Adult; Age Factors; Anticholesteremic Agents; Asymptomatic Diseases; ATP Binding Cassette Transporter, Subfamily G, Member 8; Biomarkers; Canada; Child; Child, Preschool; Cholesterol; Ezetimibe; Female; Genetic Predisposition to Disease; Homeostasis; Humans; Hypercholesterolemia; Infant; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mutation; Phenotype; Phytosterols; Prevalence; Puberty; Rare Diseases; Risk Factors; Sitosterols; Time Factors; Treatment Outcome; United States; Young Adult | 2018 |
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sitosterols; Time Factors; Treatment Outcome | 2018 |
Call for an ezetimibe effectiveness test.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
Reply to: "Call for an ezetimibe effectivess test".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5.
Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol; Cholesterol, LDL; Diagnostic Errors; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Loss of Function Mutation; Middle Aged; Phytosterols; Sitosterols; Treatment Failure | 2020 |